| Vifor (International) Inc. - Flucelvax Tetra, Injektionssuspension | | 67482 | | 02 | | Flucelvax Tetra | | Injektionssuspension | | J07BB02 | | Influenza, gereinigtes Antigen | | 19.07.2024 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Wisconsin/67/2022 (H1N1)-like: derived from A/Georgia/12/2022 CVR-167) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Massachusetts/18/2022 (H3N2)-like: derived from A/Sydney/1304/2022) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant from B/Singapore/WUH4618/2021 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013-like: reassortant from B/Singapore/INFTT-16-0610/2016 (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum. | | Packungsbestandteile | | Suspension injectable | | | | | | | | Principe actif | Concentr. |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus Stamm A/wisconsin/67/2022 (H1N1)-Like: Derived from A/georgia/12/2022 Cvr-167) | 15µg / 0.5ml | | Haemagglutininum Influenzae a (H3N2) (Virus Stamm A/massachusetts/18/2022 (H3N2)-Like: Derived from A/sydney/1304/2022) | 15µg / 0.5ml | | Haemagglutininum Influenzae b (Virus Stamm B/austria/1359417/2021-Like: Reassortant from B/singapore/wuh4618/2021 (Victoria Lineage)) | 15µg / 0.5ml |
| | BAG: Principe actif | Concentr. |
|---|
| Influenza-haemagglutinine | 0.06 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Haemagglutininum Influenzae b (Virus Stamm B/phuket/3073/2013-Like: Reassortant from B/singapore/inftt-16-0610/2016 (Yamagata Lineage)) | 15µg / 0.5ml | | Potassium Chlorure | | | Potassium Dihydrogenophosphate | | | Magnesium Chloride Hexahydrate | | | Sodium Chlorure | | | Sodium Dihydrogenophosphate Dihydrate | |
| |
| |
|
